The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial

Bahrami, Mina; Cheraghpour, Makan; Jafarirad, Sima; Alavinejad, Pejman; Asadi, Fariba; Hekmatdoost, Azita; Mohammadi, Mahsa; Yari, Zahra

doi:10.1016/j.ctim.2020.102452

Cited by 32 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Bahrami et al 29 is the study with the largest positive effect of melatonin on BMI. However, at baseline, the melatonin group had an almost significantly lower BMI compared to the placebo group (p = .056), which favours melatonin treatment in this meta-analysis.…”

Section: Discussionmentioning

confidence: 99%

“…After duplicate removal, abstract screening and full-text reviews, eleven studies were included in the systematic review and meta-analysis and none was found to have been published in a predatory journal. [15][16][17][18][27][28][29][30][31][32][33]…”

Section: Study Selectionmentioning

confidence: 99%

“…Seven studies had low risk of bias 16,17,28,[30][31][32][33] and four studies had some concerns. 15,18,27,29 Abood et al 27 randomized 40 women with metabolic syndrome 1:1 to receive either 500 mg metformin × 2 and placebo × 1 or 500 mg metformin × 2 and 10 mg melatonin × 1 for 90 days. They reported significant reductions in fasting serum glucose, insulin, insulin resistance (HOMA-IR) and BMI in the melatonin group compared with the placebo group after 90 days of treatment.…”

Section: Study Characteristics and Risk Of Bias Within Studiesmentioning

confidence: 99%

“…Bahrami et al 29 randomized 50 patients with nonalcoholic fatty liver disease (NAFLD) 1:1 to either placebo or 6 mg melatonin for 12 weeks. There was no significant change in fasting blood glucose, but BMI decreased significantly after melatonin treatment.…”

Section: Study Characteristics and Risk Of Bias Within Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta‐analysis

Lauritzen

Kampmann

Smedegaard

et al. 2021

Clinical Endocrinology

View full text Add to dashboard Cite

Background: Melatonin is increasingly used as a pharmacological sleep aid but it is also emerging as a regulator of glucose homoeostasis. Yet, previous research has been ambiguous with reports of both positive and negative effects of melatonin on glucose metabolism.Objectives: To assess the effect of daily treatment with melatonin on fasting glucose, insulin, insulin sensitivity and haemoglobin A1c (HbA1c) levels.Data Sources: MEDLINE, EMBASE, CENTRAL, clinicaltrials.gov and clinicaltrialsregister.eu were systematically searched.Eligibility Criteria, Participants and Interventions: All randomized, placebo-controlled studies with melatonin treatment were assessed. We included studies with daily melatonin treatment (≥2 weeks) of healthy adults or patients with metabolic diseases.Methods: Hedges' g differences were calculated for the metabolic parameters of the included studies, heterogeneity was assessed with χ 2 and I 2 tests and meta-analyses were performed with the random-effects model. Results: Long-term treatment with melatonin did not change fasting glucose significantly compared with placebo (g: −0.07 [−0.22 to 0.08], n = 603) but it reduced fasting insulin levels slightly (g: −0.27 [−0.50 to −0.04], n = 278) and trended towards reduced insulin resistance (HOMA-IR) (g: −0.20 [−0.44 to 0.03], n = 278). HbA1c levels were largely unaffected by melatonin treatment compared with placebo (g: 0.14 [−0.19 to 0.46], n = 142).Conclusions: With the available literature, melatonin seems to be a glucosemetabolic safe sleep aid in patients with metabolic diseases and in healthy adults. It may even have beneficial glucose-metabolic effects as fasting insulin levels were reduced in this meta-analysis, but the confidence intervals of the meta-analyses are wide, underscoring the need for further research within this field.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Characteristics and Risk Of Bias Within Studiesmentioning

confidence: 99%

Section: Study Characteristics and Risk Of Bias Within Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta‐analysis

Lauritzen

Kampmann

Smedegaard

et al. 2021

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…In a RCT [119] investigating patients with NAFLD (n = 24) supplemented with 6 mg/day melatonin for 12 weeks significantly reduced levels of ALT (60 to 41 IU/L) and AST (35 to 30 IU/L), in comparison with the placebo group (n = 21). Whilst GGT levels did not change significantly, the authors have considered a tendency for reduction (35 to 31 IU/L, p = 0.07).…”

Section: Biochemical Modulation Of Hepatic Parametersmentioning

confidence: 99%

Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications

Genário

Cipolla‐Neto

Bueno

et al. 2021

Pharmacological Research

View full text Add to dashboard Cite

show abstract

Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis

Komolafe

Buzzetti

Linden

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial

Cited by 32 publications

References 31 publications

Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta‐analysis

Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta‐analysis

Melatonin supplementation in the management of obesity and obesity-associated disorders: A review of physiological mechanisms and clinical applications

Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis

Contact Info

Product

Resources

About